GLP-1 Medications and Peripheral Artery Disease: What the Research Shows

Introduction

For decades, the playbook for peripheral artery disease was narrow: control risk factors, prescribe a statin and an antiplatelet, recommend supervised exercise, and operate when the leg arteries finally closed off. Almost nothing reliably made people walk farther before the pain stopped them. The arrival of evidence on GLP-1 medications and peripheral artery disease has changed that conversation — semaglutide is now the first drug in a generation shown in a dedicated randomized trial to extend how far patients with this condition can walk.

The scale of the problem is enormous. Peripheral artery disease (PAD) narrows the arteries that carry blood to the legs, most often as a complication of atherosclerosis and type 2 diabetes, and it is far more common than most people realize.

Evidence: "An estimated 236.62 million people aged 25 years and older were living with peripheral artery disease in 2015, of whom 72.91% were in low-income and middle-income countries." — Song P, et al. Lancet Glob Health. 2019. DOI: 10.1016/S2214-109X(19)30255-4

The hallmark symptom, intermittent claudication, is a cramping leg pain that forces people to stop walking after a short distance. Beyond the lost mobility, PAD is a red flag for systemic atherosclerosis: these patients face high rates of heart attack, stroke, amputation, and death. That dual burden — limbs and heart — is exactly where GLP-1 receptor agonists are now being studied.

How GLP-1 Medications Affect Peripheral Artery Disease

GLP-1 receptor agonists were designed to lower blood sugar and, later, to drive weight loss. Their effect on diseased arteries appears to run through several overlapping mechanisms that have nothing to do with the scale.

The vascular biology is becoming clearer. A 2025 state-of-the-art review summarized the pathways through which these drugs may protect ischemic limbs.

Evidence: "GLP-1 RAs have consistently demonstrated favorable effects on limb outcomes, including reduced rates of MALEs and amputations." — Caturano A, et al. J Clin Med. 2025. DOI: 10.3390/jcm14155549

Three mechanisms stand out:

Endothelial repair. GLP-1 receptor agonists increase nitric oxide bioavailability, which relaxes blood vessels and reduces arterial stiffness — directly relevant to legs starved of blood flow.
Anti-inflammatory action. They suppress pro-inflammatory signals such as IL-6, TNF-α, and C-reactive protein, helping to stabilize atherosclerotic plaque and lower the risk of rupture.
Anti-atherosclerotic effects. They inhibit vascular smooth muscle proliferation, counter neointimal hyperplasia, and improve the lipid profile — all of which slow the underlying disease that causes PAD.

Crucially, the early signals suggest the benefit is not simply a byproduct of weight loss or better glucose numbers. The trial that anchors this field measured something patients feel directly: walking distance.

The STRIDE Trial: First Randomized Evidence in PAD

STRIDE, published in The Lancet in 2025, was the first phase 3 randomized controlled trial to test a GLP-1 medication specifically for functional outcomes in PAD. It enrolled 792 adults with type 2 diabetes and symptomatic PAD with intermittent claudication across 112 sites in 20 countries, randomizing them to subcutaneous semaglutide 1.0 mg weekly or placebo for 52 weeks.

The primary endpoint was the ratio of maximum walking distance at 52 weeks compared to baseline, measured on a treadmill set to a 12% incline — a demanding test designed to expose claudication.

Evidence: "Semaglutide increased walking distance in patients with symptomatic peripheral artery disease and type 2 diabetes." — Bonaca MP, et al. Lancet. 2025. DOI: 10.1016/S0140-6736(25)00509-4

What the Numbers Showed

Patients on semaglutide improved their maximum walking distance 13% more than those on placebo, a difference that was both statistically significant and clinically meaningful. The drug also beat placebo on every prespecified secondary endpoint, including pain-free walking distance and disease-specific quality of life measured by the VascuQoL-6 questionnaire.

Outcome (52 weeks)	Semaglutide	Placebo	Result
Max walking distance (median ratio to baseline)	1.21	1.08	Treatment ratio 1.13 (95% CI 1.06–1.21); p=0.0004
Pain-free walking distance	Improved	—	Superior to placebo
VascuQoL-6 quality of life	Improved	—	Superior to placebo
Serious adverse events	5 patients (1%)	6 patients (2%)	No treatment-related deaths

The safety profile was reassuring. Serious adverse events were actually slightly less frequent in the semaglutide group, the most common treatment-related events were the familiar gastrointestinal side effects, and there were no treatment-related deaths. For a population that often cannot tolerate or has exhausted other options, an improvement in the core symptom of the disease — with no new safety alarms — is notable.

Beyond Walking Distance: Heart and Limb Outcomes

Walking farther matters to daily life, but PAD patients die of heart attacks and lose limbs to amputation. A growing body of evidence suggests GLP-1 medications move those harder endpoints too.

A 2026 systematic review and meta-analysis pooled six randomized controlled trials covering 7,645 adults with diabetes and PAD.

Evidence: "GLP-1 receptor agonists were associated with reduced all-cause mortality (RR 0.83, 95% CI 0.70–0.99; p=0.04) and major adverse cardiovascular events (RR 0.86, 95% CI 0.76–0.98; p=0.02) in adults with diabetes and peripheral artery disease." — Shuja SH, et al. Am J Cardiol. 2026. DOI: 10.1016/j.amjcard.2025.09.039

That meta-analysis did not find a statistically significant effect on limb-specific events in the pooled randomized data — an honest reminder that the limb-protection story is still being written. Real-world data, however, point in a more favorable direction. A large retrospective analysis presented at the Society for Vascular Surgery's 2025 annual meeting matched more than 55,000 patients per group with moderate PAD.

Evidence: "At 1 year, GLP-1 receptor agonist use was associated with lower mortality (1.7% vs 4.4%), fewer major adverse cardiac events (25.4% vs 29.3%), fewer major adverse limb events (0.8% vs 1.5%), and fewer hospitalizations (17.9% vs 26.8%); all p<0.01." — Go CC, et al. J Vasc Surg. 2025. DOI: 10.1016/j.jvs.2025.05.037

The signal extends even to the sickest patients. In chronic limb-threatening ischemia — the most severe stage of PAD, where amputation is a real and immediate threat — observational data have linked GLP-1 receptor agonist use to lower five-year risk of major amputation, death, heart attack, and stroke.

Evidence: "GLP-1 receptor agonist use was associated with reduced 5-year risk of major amputation, all-cause mortality, myocardial infarction, and ischaemic stroke in patients with chronic limb-threatening ischaemia." — Yahyavi A, et al. Vasc Med. 2025. DOI: 10.1177/1358863X251393107

Evidence type	Population	Key finding
RCT (STRIDE)	792 with PAD + T2D	+13% walking distance vs placebo
Meta-analysis of 6 RCTs	7,645 with PAD + diabetes	Lower mortality and MACE; limb effect unproven
Retrospective (matched)	~110,000 with moderate PAD	Fewer deaths, cardiac, and limb events at 1 year
Retrospective (CLTI)	Severe PAD	Lower 5-year amputation and death risk

These benefits build on the broader cardiovascular protection GLP-1 drugs already provide, a theme explored in our overview of GLP-1 medications and cardiovascular benefits. Much of the limb advantage likely traces back to the same engine that drives type 2 diabetes improvement: better glycemic control, lower inflammation, and healthier arteries.

What This Means for People With PAD

The practical takeaway is measured optimism. STRIDE establishes that semaglutide can improve walking ability in people who have both type 2 diabetes and symptomatic PAD — a genuinely new therapeutic effect for a disease with few good options. The cardiovascular mortality benefit is well supported. The limb-event benefit is promising in real-world data but not yet confirmed in randomized trials.

Several caveats deserve emphasis:

The trial population had diabetes. STRIDE enrolled only people with type 2 diabetes, so whether the walking benefit extends to PAD patients without diabetes is unknown.
GLP-1 drugs are not a replacement for proven PAD care. Statins, antiplatelet therapy, smoking cessation, blood pressure control, and supervised exercise remain the foundation. These medications are an addition, not a substitute.
Side effects and access matter. Gastrointestinal effects are common early on, and cost and supply can limit who actually gets the drug.

Anyone with PAD considering a GLP-1 medication should make that decision with a clinician who can weigh their full cardiovascular and metabolic picture — including blood pressure, which these drugs also tend to lower, as covered in our piece on GLP-1 medications and blood pressure.

Limitations and Open Questions

The research base, while rapidly expanding, has clear gaps. STRIDE measured walking distance over one year, not hard limb outcomes like amputation, and ran for 52 weeks — long enough to show functional gains but short for tracking events that accumulate over years. The strongest data on amputation and limb salvage come from observational studies, which cannot prove cause and effect because patients prescribed GLP-1 drugs may differ systematically from those who are not. Dedicated randomized limb-outcome trials are the missing piece. Until they read out, the honest framing is that GLP-1 medications clearly help PAD patients walk farther and live longer, while their power to save limbs remains a strong hypothesis rather than settled fact.

Key Takeaways

The STRIDE trial is the first randomized evidence that a GLP-1 medication (semaglutide 1.0 mg weekly) improves walking distance in people with symptomatic PAD and type 2 diabetes — a 13% advantage over placebo, with no new safety concerns.
A 2026 meta-analysis of six RCTs found GLP-1 receptor agonists reduced all-cause mortality and major adverse cardiovascular events in PAD patients with diabetes.
Large real-world datasets associate these drugs with fewer deaths, cardiac events, limb events, and hospitalizations, including in severe limb-threatening disease — though randomized limb-outcome trials are still needed.
GLP-1 medications complement, but do not replace, statins, antiplatelet therapy, exercise, and risk-factor control in PAD.

For the right patient — someone with type 2 diabetes and symptomatic PAD already on guideline therapy — a GLP-1 receptor agonist now has evidence behind it that simply did not exist a few years ago.

References

Bonaca MP, et al. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet. 2025;405(10489):1580-1593. DOI: 10.1016/S0140-6736(25)00509-4
Shuja SH, et al. GLP-1 Receptor Agonists and Cardiovascular Outcomes in Adults With Diabetes and Peripheral Artery Disease: An Updated Systematic Review and Meta-Analysis. American Journal of Cardiology. 2026;258:268-275. DOI: 10.1016/j.amjcard.2025.09.039
Go CC, et al. Glucagon-like peptide-1 receptor agonists are associated with fewer major adverse cardiovascular and limb events in patients with moderate peripheral arterial disease. Journal of Vascular Surgery. 2025;82(3):1024-1032.e2. DOI: 10.1016/j.jvs.2025.05.037
Yahyavi A, et al. Benefits of GLP-1 receptor agonists on 5-year risk of major amputation, all-cause mortality, myocardial infarction, and ischemic stroke in patients with chronic limb-threatening ischemia (CLTI). Vascular Medicine. 2025. DOI: 10.1177/1358863X251393107
Caturano A, et al. SGLT2 Inhibitors and GLP-1 Receptor Agonists in PAD: A State-of-the-Art Review. Journal of Clinical Medicine. 2025;14(15):5549. DOI: 10.3390/jcm14155549
Song P, et al. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Global Health. 2019;7(8):e1020-e1030. DOI: 10.1016/S2214-109X(19)30255-4

Last updated: 2026-06-10 Medical review: Dr. James Chen, MD, PhD, FACE